Product
Margetuximab
2 clinical trials
5 indications
Indication
Breast Cancer MetastaticIndication
Breast CancerIndication
Breast Cancer, Stage IIIndication
Stage III Breast CancerIndication
Breast Cancer (HER2-positive)Clinical trial
A Randomized, Open-Label, Multiple-center, Phase II Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 TherapiesStatus: Active (not recruiting), Estimated PCD: 2021-09-03
Clinical trial
MARGetuximab Or Trastuzumab (MARGOT): A Phase II Study Comparing Neoadjuvant Paclitaxel/Margetuximab/Pertuzumab to Paclitaxel/Trastuzumab/Pertuzumab in Patients With Stage II-III HER2-positive Breast CancerStatus: Active (not recruiting), Estimated PCD: 2024-10-01